Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, May 14, 2014

Anti-Depressant Reduces Alzheimer’s Plaque Growth by 78 Percent

How closely is your doctor following this to prevent your 33% chance of getting dementia/Alzheimers post stroke?
Does your doctor even know about this?
http://www.biosciencetechnology.com/articles/2014/05/anti-depressant-reduces-alzheimer%E2%80%99s-plaque-growth-78-percent? 

A common antidepressant can dramatically halt growth of Alzheimer’s plaque.
A team from Missouri and Pennsylvania report today in Science Translational Medicine this reduction occurs in both humans and mice. It gives the drug, the selective serotonin reuptake inhibitor (SSRI) citalopram, a possible future role as a prophylactic—the first in Alzheimer’s disease (AD), if bigger studies are supportive.
“I was surprised the effect on plaque growth and prevention in transgenic mice was so large,” first author Yvette Sheline told Bioscience Technology. Sheline is director of the University of Pennsylvania Center for Neuromodulation in Depression and Stress. “We are hopeful that we can proceed in a systematic way to develop a preventive treatment for AD.”

More at link.

No comments:

Post a Comment